La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Edwards Lifesciences Bilan de santé
Santé financière contrôle des critères 6/6
Edwards Lifesciences possède un total de capitaux propres de $7.5B et une dette totale de $597.3M, ce qui porte son ratio d'endettement à 8%. Son actif total et son passif total sont $10.1B et de $2.6B. L'EBIT de Edwards Lifesciences est $1.9B ce qui fait que son ratio de couverture des intérêts -29.4. Elle dispose de liquidités et de placements à court terme de $2.0B.
Informations clés
8.0%
Ratio d'endettement
US$597.30m
Dette
Ratio de couverture des intérêts | -29.4x |
Argent liquide | US$1.99b |
Fonds propres | US$7.50b |
Total du passif | US$2.59b |
Total des actifs | US$10.10b |
Mises à jour récentes de la santé financière
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Recent updates
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 30Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Jun 15Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed
Jun 12Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
May 31Analyse de la situation financière
Passif à court terme: Les actifs à court terme de EW ( $4.5B ) dépassent ses passifs à court terme ( $1.2B ).
Passif à long terme: Les actifs à court terme de EW ( $4.5B ) dépassent ses passifs à long terme ( $1.4B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: EW dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de EW a été réduit de 17% à 8% au cours des 5 dernières années.
Couverture de la dette: La dette de EW est bien couverte par le flux de trésorerie opérationnel ( 145% ).
Couverture des intérêts: EW gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.